Pacific Shuanglin Bio-pharmacy Co., LTD (SHE:000403)

Market Cap	16.02B
Revenue (ttm)	2.84B
Net Income (ttm)	828.65M
Shares Out	731.07M
EPS (ttm)	1.14
PE Ratio	19.30
Forward PE	18.19
Dividend	0.30 (1.37%)
Ex-Dividend Date	Dec 17, 2024

Volume	6,177,366
Average Volume	6,480,059
Open	21.79
Previous Close	21.89
Day's Range	21.78 - 22.18
52-Week Range	19.46 - 30.64
Beta	0.49
RSI	58.12
Earnings Date	Apr 24, 2025

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,426
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2023, SHE:000403's revenue was 2.33 billion, a decrease of -3.18% compared to the previous year's 2.41 billion. Earnings were 612.11 million, an increase of 4.25%.